References
- Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med 2000;160:1074–81.
- Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton JRJr, Nguyen J, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254–9.
- Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, et al. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med 2008;168:1371–86.
- Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008;46:550–6.
- Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005;26:414–19.
- Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:62–8.
- Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500–11.
- Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol 2006;101:110–18.
- Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics 2001;57:120–5.
- Whitlock TL, Tignor A, Webster EM, Repas K, Conwell D, Banks PA, et al. A scoring system to predict readmission of patients with acute pancreatitis to the hospital within thirty days of discharge. Clin Gastroenterol Hepatol 2011;9:175–80; quiz e18.
- Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–11.
- Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012;6:681–6.
- Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol 2012;27:487–92.
- Ananthakrishnan AN, Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane I, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:789–95.
- Horwich TB, Hernandez AF, Liang L, Albert NM, Labresh KA, Yancy CW, et al. Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes. Am Heart J 2009;158:451–8.
- Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am 2009;38:577–94.
- Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.